Arcutis Biotherapeutics, Inc. ARQT Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost?
- Arcutis Biotherapeutics, Inc. (ARQT) reported available-for-sale debt securities - amortized cost of $140.44M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost decreased by 3.0% year-over-year, from $144.8M to $140.44M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s available-for-sale debt securities - amortized cost has grown at a -8.8% compound annual growth rate (CAGR), from $219.36M to $138.28M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.